Neomycin + Placebo + Rifaximin
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Constipation-predominant Irritable Bowel Syndrome
Conditions
Constipation-predominant Irritable Bowel Syndrome
Trial Timeline
Aug 1, 2009 → Jun 1, 2013
NCT ID
NCT00945334About Neomycin + Placebo + Rifaximin
Neomycin + Placebo + Rifaximin is a pre-clinical stage product being developed by Bausch Health for Constipation-predominant Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00945334. Target conditions include Constipation-predominant Irritable Bowel Syndrome.
Hype Score Breakdown
Clinical
3
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00945334 | Pre-clinical | Completed |
Competing Products
1 competing product in Constipation-predominant Irritable Bowel Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| linaclotide + placebo | Astellas Pharma | Phase 2 | 35 |